About ImmunoBrain Checkpoint

About company

ImmunoBrain Checkpoint, Inc. is a biopharmaceutical company focused on developing a pipeline of novel disease-modifying immunotherapies for neurological disorders by targeting immune checkpoint pathways. IBC’s novel approach for treatment of neurodegeneration is based on years of innovative, cutting edge scientific discoveries made by Prof. Michal Schwartz (Weizmann Institute of Science, Israel).